-
公开(公告)号：WO2021091535A1
公开(公告)日：2021-05-14
申请号：PCT/US2019/059813
申请日：2019-11-05
IPC分类号： A61K31/497 , A61K31/506 , A61K31/519 , A61K31/5377 , A61K31/55 , A61P35/00 , A61P35/02
摘要： The present disclosure relates to the use of 2-((4S)-6-(4-chlorophenyl)-1-methyl-4H-benzo[c]isoxazolo[4,5-e]azepin-4-yl)acetamide in combination with JAK inhibitors for treating myelofibrosis.
-
公开(公告)号：WO2021021893A1
公开(公告)日：2021-02-04
申请号：PCT/US2020/044014
申请日：2020-07-29
IPC分类号： A61K31/44 , A61K31/4439 , A61P25/00 , A61P25/28
摘要： Provided are methods for treating neurological disorders using compounds of Formula (I), and pharmaceutically acceptable salts and compositions thereof.
-
公开(公告)号：WO2020256739A1
公开(公告)日：2020-12-24
申请号：PCT/US2019/038506
申请日：2019-06-21
IPC分类号： A61K31/55 , A61K31/519 , A61K31/5377 , A61K31/496 , A61K31/506 , A61P35/00 , A61P35/02
摘要： The present disclosure relates to the use of 2-((4S)-6-(4-chlorophenyl)-1-methyl-4H- benzo[c]isoxazolo[4,5-e]azepin-4-yl)acetamide in combination with JAK inhibitors for treating myelofibrosis.
-
4.发明申请
公开(公告)号：WO2020139943A1
公开(公告)日：2020-07-02
申请号：PCT/US2019/068575
申请日：2019-12-26
IPC分类号： A61K31/4166 , A61K31/4545 , A61K31/58 , A61P35/00 , A61K31/573
摘要： Provided herein are methods of using (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide, or a pharmaceutically acceptable salt thereof and an androgen receptor signaling inhibitor for treating prostate cancer. Also provided are pharmaceutical compositions comprising (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2- methyl- 1-( 1-( 1-(2, 2, 2-trifluoroethyl)piperidin-4-yl)ethyl)-1H- indole-3-carboxamide, or a pharmaceutically acceptable salt thereof and an androgen receptor signaling inhibitor.
-
5.发明申请
公开(公告)号：WO2020139339A1
公开(公告)日：2020-07-02
申请号：PCT/US2018/067646
申请日：2018-12-27
IPC分类号： A61K31/4166 , A61K31/4545 , A61K31/58 , A61P35/00 , A61K31/573
摘要： Provided herein are methods of using (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide, or a pharmaceutically acceptable salt thereof and an androgen receptor signaling inhibitor for treating prostate cancer. Also provided are pharmaceutical compositions comprising (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1 H-indole-3-carboxamide, or a pharmaceutically acceptable salt thereof and an androgen receptor signaling inhibitor.
-
公开(公告)号：WO2020112939A8
公开(公告)日：2020-06-04
申请号：PCT/US2019/063515
申请日：2019-11-27
IPC分类号： A61K31/55 , A61K31/519 , A61P7/06 , A61P35/00 , A61P35/02
摘要： The present disclosure relates to the use of 2-((4S)-6-(4-chlorophenyl)-l-methyl-4H- benzo [c] isoxazolo [4,5-e] azepin-4-yl)acetamide, and pharmaceutically acceptable salts thereof, for treating myelofibrosis.
-
公开(公告)号：WO2020112939A1
公开(公告)日：2020-06-04
申请号：PCT/US2019/063515
申请日：2019-11-27
IPC分类号： A61K31/55 , A61K31/519 , A61P7/06 , A61P35/00 , A61P35/02
摘要： The present disclosure relates to the use of 2-((4S)-6-(4-chlorophenyl)-l-methyl-4H- benzo [c] isoxazolo [4,5-e] azepin-4-yl) acetamide, and pharmaceutically acceptable salts thereof, for treating myelofibrosis.
-
公开(公告)号：WO2019161162A1
公开(公告)日：2019-08-22
申请号：PCT/US2019/018158
申请日：2019-02-15
IPC分类号： C07D401/14 , A61K31/404 , A61K31/415 , A61K31/4164 , A61K31/4439 , A61K31/451 , A61K31/4709 , A61K31/495 , A61K31/50 , A61K31/505 , A61K31/506 , C07D231/12 , C07D233/64 , C07D401/04 , C07D403/04 , C07D237/08 , C07D239/26 , C07D241/04 , C07D211/32 , A61P11/00 , A61P3/00 , A61P9/00 , A61P29/00 , A61P35/00 , A61P31/12
摘要： Provided are compounds of Formula (I): and pharmaceutically acceptable salts and compositions thereof, which are useful for treating a variety of conditions associated with histone acetyltransferase (HAT).
-
9.发明申请HETEROCYCLIC INHIBITORS OF CBP/EP300 AND THEIR USE IN THE TREATMENT OF CANCER 审中-公开CBP / EP300杂环抑制剂及其在癌症治疗中的应用
公开(公告)号：WO2017205536A3
公开(公告)日：2017-11-30
申请号：PCT/US2017/034320
申请日：2017-05-24
发明人： CYR, Patrick , BRONNER, Sarah , ROMERO, F. Anthony , MAGNUSON, Steven , TSUI, Vickie Hsiao-Wei , WAI, John , LAI, Kwong Wah , WANG, Fei
IPC分类号： C07D401/14 , C07D405/14 , C07D413/14 , C07D409/14 , C07D413/04 , C07D413/10 , C07D243/14 , C07D417/14 , C07D471/04 , C07D487/04 , C07D267/14 , A61K31/5513 , A61K31/553 , A61K31/475 , A61P35/00
摘要： The present invention relates to compounds of formula (I) and formula (II): and to salts thereof, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) of formula (II), or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders such as cancer, inflammatory disorders and autoimmune diseases.
摘要翻译： 本发明涉及式（I）和式（II）的化合物及其盐，以及其组合物和用途。 该化合物可用作CBP和/或EP300的抑制剂。 还包括药物组合物，其包含式（II）的式（I）化合物或其药学上可接受的盐，以及在治疗各种CBP和/或EP300介导的疾病如癌症中使用此类化合物和盐的方法 ，炎性疾病和自身免疫性疾病。
-
公开(公告)号：WO2017205536A2
公开(公告)日：2017-11-30
申请号：PCT/US2017/034320
申请日：2017-05-24
发明人： CYR, Patrick , BRONNER, Sarah , ROMERO, F. Anthony , MAGNUSON, Steven , TSUI, Vickie Hsiao-Wei , WAI, John , LAI, Kwong Wah , WANG, Fei
IPC分类号： C07D401/14 , C07D405/14 , C07D413/14 , C07D409/14 , C07D413/04 , C07D413/10 , C07D243/14 , C07D417/14 , C07D471/04 , C07D487/04 , C07D267/14 , A61K31/5513 , A61K31/553 , A61K31/475 , A61P35/00
摘要： The present invention relates to compounds of formula (I) and formula (II): and to salts thereof, wherein R 1 -R 4 of formula (I) and R 5 -R 6 of formula (II) have any of the values defined herein, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) of formula (II), or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders.
摘要翻译： 本发明涉及式（I）和式（II）的化合物及其盐，其中R 1 -R 4， （I）和式（II）的R 5 -R 6具有本文所定义的任何值，及其组合物和用途。 该化合物可用作CBP和/或EP300的抑制剂。 还包括包含式（II）的式（I）化合物或其药学上可接受的盐的药物组合物，以及使用该化合物和盐治疗各种CBP和/或EP300介导的病症的方法。 p>
-
-
-
-
-
-
-
-
-
搜索结果
98 条记录 (耗时 0.021 秒)
